ADCs and radiopharmaceuticals at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

39 organizations at ENA 2026 present work in antibody–drug conjugates and radiopharmaceuticals: 24 drug developers, 10 cancer centres and hospitals, 3 CROs and suppliers and 2 universities and institutes. Between them they bring 84 presentations to the program. Most represented: MD Anderson Cancer Center, Biocytogen and NEXT Oncology. As of Oct 13, 2026.

All 254 organizations at ENA 2026 →

Showing 1–9 of 39 organizations

Organization	ENA 2026 Attendance
MD Anderson Cancer Center Houston, Texas
mdanderson.org Cancer centres & hospitals University of Texas cancer centre for patient care, research and early-phase clinical trials.	Session Wed Nov 18 4:15–5:45pm Workshop 2: Radiopharmaceuticals ADCs & radioligands Talk Wed Nov 18 4:55–5:15pm Part of Workshop 2: Radiopharmaceuticals Translating Radiopharmaceutical Innovation from Bench to Bedside ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Translational validation of uPARAP (MRC2) as an antibody–drug conjugate target in osteosarcoma patient-derived xenograft models ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Preliminary phase 1 results from AVENTINE-1, a phase 1/2 study of AVZO-1418, an EGFR-HER3 bispecific antibody-drug conjugate (BsADC) for the treatment of patients with locally advanced or metastatic solid tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Population pharmacokinetics (popPK) and exposure-response analyses of sacituzumab tirumotecan (sac-TMT) antibody-drug conjugate (ADC) in participants (pts) with advanced solid tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers TROP2 Predicts Response to TUSC2 Gene Therapy (Quaratusugene Ozeplasmid) and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment Targeted agents Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Targeting the PI4K2A lysosomal pathway is a promising approach for lung cancer therapy Biomarkers Talk Thu Nov 19 10–10:10am Part of Plenary Session 3: Proffered Papers Phase 1 trial and translational study of the glutaminase-1 (GLS1) inhibitor IACS-6274 in combination with bevacizumab and paclitaxel in patients with advanced ovarian cancer Early clinical · Targeted agents Session Thu Nov 19 2–2:30pm Posters in the Spotlight, session 1 Session Thu Nov 19 3–4:30pm Workshop 3: End-to-End Early Clinical Development Through AI AI · Early clinical Session Thu Nov 19 3–4:30pm Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Genomics Talk Thu Nov 19 3:20–3:40pm Part of Workshop 3: End-to-End Early Clinical Development Through AI Radiology - Digital twins and multiomics AI · Early clinical Talk Thu Nov 19 3:40–4pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Rewiring the Cell Cycle: Early Clinical Insights from Next-Generation Cyclin and CDK Targeting Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Delivery A Bayesian pharmacokinetics-integrated Phase I–II design to optimize dose-schedule regimes Drug design Talk Fri Nov 20 3–3:10pm Part of Plenary Session 7: Proffered papers Interim results from the ﬁrst-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) Early clinical · Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Discovery of novel combination strategies to target SWI/SNF mutant lung cancers Targeted agents
Biocytogen Beijing, China
biocytogen.com CROs & CDMOsExhibitor Provides humanized mouse models, preclinical pharmacology and antibody discovery, and develops its own antibody and ADC candidates.	Booth Exhibiting at Booth 23 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors ADCs & radioligands Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology BCG024: A Novel DLL3×CD3×4-1BB Trispecific T Cell Engager Enhances T Cell Persistence and Functionality in Preclinical Models Immuno-oncology Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Animal Models The B-hCRBN Mice Model Facilitates PROTACs Studies Based on CRBN Ligands Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Animal Models Utilizing a Humanized CD8 Mouse Model for Non-clinical Studies of Cancer Immunotherapy Preclinical models
NEXT Oncology San Antonio, Texas
nextoncology.com Cancer centres & hospitals Network of phase 1 cancer clinical trial sites in the US, Spain and other countries.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates First Results from a First-in-Human Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502, an anti-Nectin-4 ADC, as a Single Agent in Advanced Solid Tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Lineage- and allele-specific coupling of KRAS alterations with NF-kB inflammatory pathway activity in solid tumours Biomarkers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Novel clinical trial design A First-in-Human Phase 1/2 Study of SAR449336, an Oral Non-Covalent Pan-KRAS Inhibitor, in Patients With Advanced KRAS-Mutant Solid Tumors (Trial in Progress) Early clinical
Dana-Farber Cancer Institute Boston, MA
dana-farber.org Cancer centres & hospitals Harvard-affiliated cancer treatment and research centre.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Nectin-4 as a therapeutic target in vulvar squamous cell carcinoma and other gynecologic cancers ADCs & radioligands Talk Thu Nov 19 12:30–12:50pm Part of Plenary Session 4: Antibody-Drug Conjugates (ADCs) Antibody drug conjugates: From breakthroughs to clinical practice ADCs & radioligands Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents SF3B1 splicing modulation to overcome platinum and PARP inhibitor resistance in ovarian cancer Targeted agents
Institut Curie Paris, France
curie.fr Cancer centres & hospitals Cancer centre combining a research centre and hospital, with translational work on patient-derived models.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates INA03, a MMAE-based ADC targeting the transferrin receptor CD71, demonstrates potent antitumor activity in breast cancer PDX models resistant to TOP1-ADCs ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates A proliferative-luminal phenotype predicts trastuzumab deruxtecan sensitivity independent of HER2 expression in ER-positive breast cancer ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Unfolded Protein Response as a Driver of Carboplatin-Paclitaxel Resistance in Ovarian Cancer Patient-Derived Xenografts Targeted agents
Novartis Basel, Switzerland
novartis.com Large pharma Global pharmaceutical company with oncology medicines including radioligand therapies and targeted agents.	Talk Wed Nov 18 5:15–5:35pm Part of Workshop 2: Radiopharmaceuticals Implementing Radioligand Therapy early trials in the Real World: Site selection, Implementation, and Supply-Chain Challenges ADCs & radioligands Session Fri Nov 20 9:30–10:45am Workshop 8: Proximity inducers beyond current PROTACs Drug design Talk Fri Nov 20 9:30–9:35am Part of Workshop 8: Proximity inducers beyond current PROTACs Setting the scene: The new world of proximity inducing therapeutics Drug design
Oncolines Oss, Netherlands
oncolines.com CROs & CDMOs Precision medicine services company profiling cancer drugs across large cell line panels.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Insights into resistance mechanisms against antibody-drug conjugates using large cancer cell panel profiling ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Characterization and targeting of adaptive KRASG12C inhibitor resistance through large-scale drug combination screening Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Molecular glue stabilization of the β-catenin/14-3-3 interaction as a novel strategy to modulate Wnt signaling Targeted agents
START Center for Cancer Research San Antonio, TX
startresearch.com Cancer centres & hospitals Network of early-phase oncology clinical trial sites in the United States and Europe, including units in Madrid.	Talk Wed Nov 18 3–3:20pm Part of Plenary Session 1: The next wave of immune engagers in cancer therapy: beyond CD3 and beyond T cells Next generation multispecific immune engagers Immuno-oncology Session Wed Nov 18 4:15–5:45pm Workshop 2: Radiopharmaceuticals ADCs & radioligands Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Safety and Preliminary Activity of MTA-Cooperative PRMT5 Inhibitors (MTA-iPRMT5) in Patients with Advanced Solid Tumors Treated in a Phase I Clinical Trials Unit Drug design
WuXi AppTec Shanghai, China
wuxiapptec.com CROs & CDMOsExhibitor Contract research, development and manufacturing organization offering drug discovery, in vivo pharmacology, testing and manufacturing services.	Booth Exhibiting at Booth 9 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Breaking through ADC resistance: generating TOP1 mutation cancer model and evaluating next generation ADCs ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Divergent mechanisms of acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib in KRAS mutant cancer Targeted agents